Mangoceuticals (MGRX) S-1/A 12 Dec 23 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT NO. 1
Entity Registrant Name	Mangoceuticals, Inc.
Entity Central Index Key	0001938046
Entity Tax Identification Number	87-3841292
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	15110 N. Dallas Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75248
City Area Code	(214)
Local Phone Number	242-9619
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	15110 N. Dallas Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75248
Contact Personnel Name	Jacob D. Cohen

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 1,236,747	$ 682,860	$ 22,550
Inventory	21,581
Prepaid expenses	84,382	11,745
TOTAL CURRENT ASSETS	1,342,710	694,605	22,550
FIXED ASSETS
Property and equipment, net of accumulated depreciation of $3,863	102,420	117,499
TOTAL FIXED ASSETS	102,420	117,499
OTHER ASSETS
Deposits	16,942	16,942
Right of use - asset	133,433	174,241
TOTAL OTHER ASSETS	150,375	191,183
TOTAL ASSETS	1,595,505	1,003,287	22,550
CURRENT LIABILITIES
Accounts payable and accrued liabilities	89,059	33,675
Payroll tax liabilities	8,200	2,717
Right-of-use liability - operating lease	61,917	56,725
TOTAL CURRENT LIABILITIES	159,176	260,577	39,270
LONG-TERM LIABILITIES
Right-of-use liability - operating lease	81,508	128,680
TOTAL LONG-TERM LIABILITIES	81,508	128,680
TOTAL LIABILITIES	240,684	389,257	39,270
COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock (par value $.0001, 200,000,000 shares authorized, of which 13,365,000 and 8,000,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively)	1,679	1,337	800
Additional paid in capital	10,013,268	2,628,449	181
Accumulated deficit	(8,660,126)	(2,015,756)	(17,701)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	1,354,821	614,030	(16,720)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	1,595,505	1,003,287	22,550
Related Party [Member]
CURRENT LIABILITIES
Notes payable		89,200	39,270
Nonrelated Party [Member]
CURRENT LIABILITIES
Notes payable		$ 78,260

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 22,461	$ 3,863
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, shares issued	16,789,500	13,365,000	8,000,000
Common stock, shares outstanding	16,789,500	13,365,000	8,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenues
Revenues	$ 245,160			$ 487,119		$ 8,939
Cost of revenues	52,193			101,538
Cost of revenues ($3,255 of related party cost of revenues for the year ended December 31, 2022)						(4,089)
Cost of revenues - related party	48,378			96,663
Gross profit (loss)	144,589			288,918		4,850
Operating expenses
General and administrative expenses	1,944,049	991,825	17,520	6,939,761	1,319,727	1,996,432
Total operating expenses	1,944,049	991,825	17,520	6,939,761	1,319,727	1,996,432
Loss from operations	(1,799,460)	(991,825)	(17,520)	(6,650,843)	(1,319,727)	(1,991,582)
Other expense
Imputed interest – related party		3,090	181	(6,473)	4,673	6,473
Total other expense		3,090	181	(6,473)	4,673	6,473
Loss before income taxes	(1,799,460)	(994,915)	(17,701)	(6,644,370)	(1,324,400)	(1,998,055)
Income taxes
Net income (loss)	$ (1,799,460)	$ (994,915)	$ (17,701)	$ (6,644,370)	$ (1,324,400)	$ (1,998,055)
Basic and diluted loss per share
Earnings per share, basic	$ (0.11)	$ (0.10)	$ 0	$ (0.45)	$ (0.13)	$ (0.19)
Earnings per share, diluted	$ (0.11)	$ (0.10)	$ 0	$ (0.45)	$ (0.13)	$ (0.19)
Basic and diluted loss per share
Weighted average number of shares outstanding, Basic	15,923,588	10,049,100	8,000,000	14,923,461	9,913,388	10,798,083
Weighted average number of shares outstanding, Diluted	15,923,588	10,049,100	8,000,000	14,923,461	9,913,388	10,798,083

Statements of Operations (Paren

Statements of Operations (Parenthetical)	12 Months Ended
	Dec. 31, 2022 USD ($)
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Cost of revenues - related party	$ 3,255

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Oct. 06, 2021
Balance, shares at Oct. 06, 2021
Imputed Interest		181		181
Net Loss			(17,701)	(17,701)
Issuance of Common Stock for Services	$ 800			800
Issuance of common stock for services, shares	8,000,000
Balance at Dec. 31, 2021	$ 800	181	(17,701)	(16,720)
Balance, shares at Dec. 31, 2021	8,000,000
Imputed Interest		889		889
Net Loss			(19,599)	(19,599)
Balance at Mar. 31, 2022	$ 800	1,070	(37,300)	(35,430)
Balance, shares at Mar. 31, 2022	8,000,000
Balance at Dec. 31, 2021	$ 800	181	(17,701)	(16,720)
Balance, shares at Dec. 31, 2021	8,000,000
Net Loss				(1,324,400)
Balance at Sep. 30, 2022	$ 1,202	2,164,770	(1,342,400)	823,572
Balance, shares at Sep. 30, 2022	12,015,500
Balance at Dec. 31, 2021	$ 800	181	(17,701)	(16,720)
Balance, shares at Dec. 31, 2021	8,000,000
Imputed Interest		6,473		6,473
Net Loss			(1,998,055)	(1,998,055)
Issuance of Common Stock for Services	$ 337	539,728		540,065
Issuance of common stock for services, shares	3,365,000
Options and Warrants Vested for Services		234,088		234,088
Issuance of Units for Cash	$ 200	1,999,800		2,000,000
Issuance of common stock for cash, shares	2,000,000
Warrants for Services Cancelled		(151,821)		(151,821)
Balance at Dec. 31, 2022	$ 1,337	2,628,449	(2,015,756)	614,030
Balance, shares at Dec. 31, 2022	13,365,000
Balance at Mar. 31, 2022	$ 800	1,070	(37,300)	(35,430)
Balance, shares at Mar. 31, 2022	8,000,000
Imputed Interest		1,583		1,583
Net Loss			(310,185)	(310,185)
Issuance of Common Stock for Services	$ 225	224,775		225,000
Issuance of common stock for services, shares	2,250,000
Balance at Jun. 30, 2022	$ 1,025	227,428	(347,485)	(119,032)
Balance, shares at Jun. 30, 2022	10,250,000
Imputed Interest		2,202		2,202
Net Loss			(994,915)	(994,915)
Issuance of Common Stock for Services	$ 27	264,973		265,000
Issuance of common stock for services, shares	265,000
Options and Warrants Vested for Services		169,817		169,817
Issuance of Units for Cash	$ 150	1,500,350		1,500,500
Issuance of common stock for cash, shares	1,500,500
Balance at Sep. 30, 2022	$ 1,202	2,164,770	(1,342,400)	823,572
Balance, shares at Sep. 30, 2022	12,015,500
Balance at Dec. 31, 2022	$ 1,337	2,628,449	(2,015,756)	614,030
Balance, shares at Dec. 31, 2022	13,365,000
Imputed Interest		1,760		1,760
Net Loss			(2,560,885)	(2,560,885)
Issuance of Common Stock for Services	$ 70	699,930		700,000
Issuance of common stock for services, shares	700,000
Options and Warrants Vested for Services		64,271		64,271
Issuance of Units for Cash	$ 125	4,999,875		5,000,000
Issuance of common stock for cash, shares	1,250,000
Balance at Mar. 31, 2023	$ 1,532	8,394,285	(4,576,641)	3,819,176
Balance, shares at Mar. 31, 2023	15,315,000
Balance at Dec. 31, 2022	$ 1,337	2,628,449	(2,015,756)	614,030
Balance, shares at Dec. 31, 2022	13,365,000
Net Loss				(6,644,370)
Balance at Sep. 30, 2023	$ 1,679	10,013,268	(8,660,126)	1,354,821
Balance, shares at Sep. 30, 2023	16,789,500
Balance at Mar. 31, 2023	$ 1,532	8,394,285	(4,576,641)	3,819,176
Balance, shares at Mar. 31, 2023	15,315,000
Imputed Interest		(8,233)		(8,233)
Net Loss			(2,284,025)	(2,284,025)
Issuance of Common Stock for Services	$ 37	386,963		387,000
Issuance of common stock for services, shares	375,000
Options and Warrants Vested for Services		64,271		64,271
Warrants exercised for cash	$ 102	1,024,398		1,024,500
Warrants exercised for cash, shares	1,024,500
Balance at Jun. 30, 2023	$ 1,671	9,861,684	(6,860,666)	3,002,689
Balance, shares at Jun. 30, 2023	16,714,500
Net Loss			(1,799,460)	(1,799,460)
Issuance of Common Stock for Services	$ 8	84,742		84,750
Issuance of common stock for services, shares	75,000
Options and Warrants Vested for Services		66,842		66,842
Balance at Sep. 30, 2023	$ 1,679	$ 10,013,268	$ (8,660,126)	$ 1,354,821
Balance, shares at Sep. 30, 2023	16,789,500

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,701)	$ (6,644,370)	$ (1,324,400)	$ (1,998,055)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation		18,598		3,863
Issuance of common stock for services		1,171,750	490,000	540,065
Imputed interest expense	181	(6,473)	4,673	6,473
Options vested for stock based compensation		195,384	169,817	234,088
Warrants for service cancelled				(151,821)
(Increase) decrease in operating assets:
Rent deposit				(16,942)
Inventory		(21,581)
Prepaid expenses		(72,637)	(37,719)	(11,745)
Operating lease right of use asset		40,808		(174,241)
(Decrease) increase in operating liabilities:
Accounts payable		55,384		33,675
Operating lease right of use liabilities		(41,980)		185,405
Payroll tax liabilities		5,483	671	2,717
NET CASH USED IN OPERATING ACTIVITIES	(17,520)	(5,299,634)	(696,958)	(1,346,518)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(3,519)	(2,531)	(43,102)
NET CASH USED IN INVESTING ACTIVITIES		(3,519)	(2,531)	(43,102)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings on notes payable to related parties	39,270		75,000	75,000
Repayment on notes payable		(78,260)
Repayment of borrowings - related parties		(89,200)	(25,070)	(25,070)
Proceeds from exercise of warrants		1,024,500
Proceeds from sales of units for cash	800	5,000,000	1,500,500	2,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	40,070	5,857,040	1,550,430	2,049,930
NET INCREASE IN CASH AND CASH EQUIVALENTS	22,550	553,887	850,941	660,310
CASH AND CASH EQUIVALENTS:
Beginning of period		682,860	22,550	22,550
End of period	22,550	1,236,747	873,491	682,860
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Accounts payable for purchase of property and equipment				$ 78,260

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF THE BUSINESS	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF THE BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”), was incorporated in the State of a Texas on October 7, 2021 www.MangoRx.com Initial Public Offering. 1,250,000 4.00 4.35 4,765,000 2,000,000 1.00	NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”), was incorporated in the State of a Texas on October 7, 2021 www.MangoRx.com Mangoceuticals plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor’s prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides. Impact of COVID-19 Pandemic on Consolidated Financial Statements. Moving forward, economic recessions, increased inflation and/or interest rates, including those brought on by the continued COVID-19 outbreak may have a negative effect on the demand for our services and our operating results. Any prolonged disruption to our operations or workforce availability is likely to have a significant adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continue.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Preparation The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) under the accrual basis of accounting. These financial statements are presented in U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the years ended December 31, 2022 and 2021 included in the Company’s Registration Statement on Form S-1 (Amendment No. 4), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (the “Form S-1”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the Form S-1 have been omitted. Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures a total cash balance of up to $ 250,000 no Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share 1,400,000 1,250,000 1,063,000 2,000,000 Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ - Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5 Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers. Black Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation Revenue Recognition Our Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Marketing and advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations $ 1,633,528 0 Subsequent events The Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, Subsequent Events	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Basis of Preparation Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $ 250,000 no Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”) 740, Income Taxes Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earnings per Share 1,250,000 2,000,000 Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ - Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5 Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers. Binomial Calculation Model Black Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial statements. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. Revenue Recognition Our Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue is generated by selling directly to consumers through our websites. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Subsequent events The Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, Subsequent Events

PREPAID EXPENSES AND DEPOSITS

PREPAID EXPENSES AND DEPOSITS	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses And Deposits
PREPAID EXPENSES AND DEPOSITS	NOTE 3 – PREPAID EXPENSES AND DEPOSITS During the three and nine months ended September 30, 2023 and the year ended December 31, 2022, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy as a retainer to be credited towards future product sales. As of September 30, 2023 and December 31, 2022, the balance was $ 84,382 11,745 Additionally, the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $ 16,942	NOTE 3 – PREPAID EXPENSES PREPAID EXPENSES AND DEPOSITS During the year ended December 31, 2022, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepaid the related party Contracted Pharmacy $ 15,000 11,745 0 16,942

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORY	NOTE 4 – INVENTORY During the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company purchased inventories related to promotional merchandise intended to be sold online. As of September 30, 2023 and December 31, 2022, the inventory balance was $ 21,581 0

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT During the nine months ended September 30, 2023, the Company acquired custom product packaging equipment totaling $ 3,519 18,598 0 102,420 117,499 SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, December 31, Computers $ 5,062 $ 5,062 Equipment 119,819 116,300 Less accumulated depreciation: (22,461 ) (3,863 ) Property and equipment, net $ 102,420 $ 117,499	NOTE 4 – PROPERTY AND EQUIPMENT During the year ended December 31, 2022, the Company acquired computers, office and custom product packaging equipment totaling $ 121,362 3,863 0 117,499 0 SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2022 December 31, 2021 Computers 5,062 - Equipment 116,300 - Less accumulated depreciation: (3,863 ) - Property and equipment, net 117,499 -

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS On December 10, 2021 and March 18, 2022, the Company received advances of $ 39,200 50,000 89,200 8,000,000 80 90,000 89,200 On June 29, 2022, the Company received an advance of $ 25,000 25,000 89,200 0 89,200 8 8,232 On December 10, 2021, the Company received an advance of $ 70 0 0 8 For additional information on related party prepaid expenses see Note 3.	NOTE 5 – RELATED PARTY TRANSACTIONS On December 10, 2021 and March 18, 2022, the Company received advances of $ 39,200 50,000 89,200 8,000,000 80% 90,000 89,200 On June 29, 2022, the Company received an advance of $ 25,000 25,000 89,200 39,200 8% 4,674 181 On December 10, 2021, the Company received an advance of $ 70 0 70 8% 2 0 The Company’s Chief Executive Officer, Jacob D. Cohen, has made his personal credit card available for purchases on behalf of the Company to cover various general and administrative expenses. Mr. Cohen has been repaid a total of $ 248,151 For additional information on related party prepaid expense see Note 3 and for related party stock-based transactions see Note 7.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $ 78,260 5,000 31,630 63,260 0 78,260	NOTE 6 – NOTES PAYABLE On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $ 78,260 5,000 31,630 78,260

CAPITAL STOCK

CAPITAL STOCK	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
CAPITAL STOCK	NOTE 8 – CAPITAL STOCK Preferred Stock The Company is authorized to issue up to 10,000,000 0.0001 Common Stock The Company is authorized to issue 200,000,000 0.0001 16,789,500 13,365,000 On August 8, 2022, the Company began a private placement of up to $ 2,000,000 1.00 five-year 1.00 The Offering commenced on August 8, 2022 and the Company sold 2,000,000 1.00 2,000,000 2,000,000 2,000,000 1,438,299 On September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (“PHX”), which is owned by Peter “Casey” Jensen, who is a member of the Board of Directors of AMIH and a related party. Pursuant to the Consulting Agreement, PHX agreed to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX 50,000 0.28 13,921 On September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (“Elliott”), currently a professional football player in the National Football League, to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Elliott 100,000 0.28 $27,842 On September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (“Sandler”), to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler 10,000 0.28 2,784 On September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (“Chou”), to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou 5,000 0.28 1,392 On September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (“Greentree” and the “Service Agreement”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree. The Company agreed to issue Greentree 100,000 50,000 (a) $12,500 on or before September 30, 2022; (b) $12,500 on or before December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023 100,000 0.28 27,842 On October 1, 2022, the Company executed a Summary of Terms and Conditions (“Offer Letter”) with Gene Johnston (“Johnston”) appointing Johnston to serve as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Offer Letter, the Company issued Johnston 150,000 25,000 25,000 0.28 41,763 On October 13, 2022, the Company entered into Director Offer Letter agreements with each of Alex Hamilton (“Hamilton”), Dr. Kenny Myers (“Myers”) and Lorraine D’Alessio (“Alessio), compensating each of them with 75,000 225,000 0.28 20,881 On October 14, 2022, the Company issued its Project Manager, Joan Arango, 25,000 0.28 7,204 On November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (“White Unicorn”), to provide business advisory services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued White Unicorn 100,000 0.28 28,816 On December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (“Global”) to provide marketing services as reasonably requested by the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Global 100,000 0.28 28,816 On December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (“Chartered Services”), to provide strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive brand awareness to the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $ 150,000 with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000 0.28 72,039 On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“DojoLabs”), to provide various strategic marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay DojoLabs $ 100,000 50,000 1.00 100,000 On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“Bethor”), to provide strategic advisory services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Bethor 250,000 1.00 250,000 On January 6, 2023, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning. In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“Dr. Rudman”) and Mr. Jarrett Boon (“Mr. Boon”), both of whom are independent, non-Board members and non-Company employees, to the Advisory Board. Dr. Rudman will serve as Chairman of the Advisory Board. In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Rudman Consulting Agreement”), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman 25,000 2,000 1.00 25,000 In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Boon Consulting Agreement”), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon 25,000 1.00 25,000 On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of each agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. 1.00 350,000 On March 22, 2023, the Company sold 1,250,000 4.00 5,000,000 On April 24, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 1.00 75,000 On April 26, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On May 1, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the “Employment Agreement”). The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for Mrs. Hammer to receive an annual salary of $ 150,000 The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $ 1.00 50,000 On May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (“Redlime”) to provide software development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Redlime $ 300,000 180,000 1.00 180,000 On May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (“Mr. Andrew”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Mr. Andrew’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Andrew Consulting Agreement”), dated effective May 25, 2023, with Mr. Andrew, whereby the Company agreed to issue Mr. Andrew 50,000 1.10 55,000 On June 1, 2023, we entered into a Consulting Agreement with Major Dodge (“Major”), to provide acting and production related services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Major 20,000 1.10 22,000 On June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (“New To The Street”), to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for 3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company issued New To The Street 50,000 5,000 1.10 55,000 On June 6, 2023, a warrant holder exercised private placement Warrants to purchase 150,000 1.00 150,000 On June 7, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 1.00 75,000 On June 8, 2023, a warrant holder exercised private placement Warrants to purchase 24,500 1.00 24,500 On June 21, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On June 22, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On June 22, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On June 27, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (“Greentree” and the “Service Agreement”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree. The Company agreed to issue Greentree 75,000 40,000 (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024. 1.13 84,750 Options: During the year ended December 31, 2022, the Company granted a total of 1,250,000 750,000 500,000 1.10 three years On May 1, 2023, the Company granted 150,000 1.10 three years As of September 30, 2023 and December 31, 2022, $ 197,954 82,267 The following table summarizes common stock options activity: The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised - - Expired - - Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 Outstanding, September 30, 2023 1,250,000 $ 1.10 Granted 150,000 $ 1.10 Exercised - - Expired - - Outstanding, September 30, 2023 1,400,000 $ 1.10 Exercisable, September 30, 2023 454,167 $ 1.10 The weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows: Outstanding Options Exercisable Options Options Exercise Shares Life Weighted Average Shares Weighted Average $ 1.10 1,400,000 4.53 $ 1.10 454,167 $ 1.10 As of September 30, 2023, the fair value of options outstanding was $ 640,194 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 Risk free interest rate 3.64 3.30 % Volatility 224.70 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term Warrants: During the year ended December 31, 2022, the Company issued a total of 2,000,000 210,070 151,821 210,070 As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase 87,500 5.00 31,995 As of September 30, 2023 and December 31, 2022, the fair value of Warrants outstanding to investors was $ 581,264 1,438,299 The following table summarizes common stock warrant activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised - - Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 Granted 87,500 5.00 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, September 30, 2023 1,063,000 1.30 Exercisable, September 30, 2023 975,500 $ 1.00 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows: Outstanding and Vested Warrants Weighted Average Warrant Exercise Price Per Share Shares Life (Years) $ 1.00 1,063,000 3.83 As of September 30, 2023, warrants to purchase 1,063,000 3.83 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.37 0.72 Risk-free interest rate From 2.95 4.00 % Volatility From 88.92 92.87 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.	NOTE 7 – CAPITAL STOCK Preferred Stock The Company is authorized to issue up to 10,000,000 0.0001 Common Stock The Company is authorized to issue 200,000,000 0.0001 13,365,000 8,000,000 On April 6, 2022, the Company issued 1,000,000 0.10 100,000 On April 6, 2022, the Company issued 1,000,000 0.10 100,000 On June 23, 2022, the Company issued 250,000 0.10 25,000 On August 8, 2022, the Company began a private placement of up to $ 2,000,000 1.00 five-year 1.00 The Offering commenced on August 8, 2022 and the Company sold 2,000,000 1.00 2,000,000 2,000,000 2,000,000 1,438,299 On September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (“PHX”), which is owned by Peter “Casey” Jensen, who is a member of the Board of Directors of AMIH. Pursuant to the Consulting Agreement, PHX agreed to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX 50,000 0.28 13,921 On September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (“Elliott”), currently a professional football player and the running back for the Dallas Cowboys, to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Elliott 100,000 0.28 27,842 On September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (“Sandler”), to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler 10,000 0.28 2,784 On September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (“Chou”), to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou 5,000 0.28 1,392 On September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (“Greentree” and the “Service Agreement”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as Audit Manager for Greentree. The Company agreed to issue Greentree 100,000 50,000 (a) $12,500 on or before September 30, 2022; (b) $12,500 on or before December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023 100,000 0.28 27,842 On October 1, 2022, the Company executed a Summary of Terms and Conditions (“Offer Letter”) with Gene Johnston (“Johnston”) appointing Johnston to serve as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Offer Letter, the Company issued Johnston 150,000 25,000 25,000 st 0.28 41,763 On October 13, 2022, the Company approved the appointments of each of Alex Hamilton (“Hamilton”), Dr. Kenny Myers (“Myers”) and Lorraine D’Alessio (“Alessio) to serve as independent members of the Board of Directors and entered into Director Offer Letter agreements with Hamilton, Myers and D’Alessio compensating each of them with 75,000 225,000 0.28 20,881 On October 14, 2022, the Company issued its Project Manager, Joan Arango, 25,000 0.28 7,204 On November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (“White Unicorn”), to provide business advisory services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued White Unicorn 100,000 0.28 28,816 On December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (“Global”) to provide marketing services as reasonably requested by the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Global 100,000 0.28 28,816 On December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (“Chartered Services”), to provide strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive brand awareness to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $ 150,000 with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000 0.28 72,039 Options: During the year ended December 31, 2022, the Company granted options to purchase a total of 1,250,000 750,000 500,000 1.10 three years 82,267 The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised — — Expired — — Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows: Outstanding Options Exercisable Options Options Exercise Price Per Share Shares Life (Years) Weighted Average Exercise Price Shares Weighted Average Exercise Price $ 1.10 1,250,000 4.67 $ 1.10 133,333 $ 1.10 As of December 31, 2022, the fair value of options outstanding was $ 688,984 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 Risk free interest rate 3.30 % Volatility 92.54 % Dividend Yield 0 % Expected Term 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future. (4) The Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine the overall expected term. Warrants: During the year ended December 31, 2022, the Company issued a total of 2,000,000 210,070 151,821 210,070 As of December 31, 2022, the fair value of Warrants outstanding to investors was $ 1,438,299 The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised — — Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows: Warrants Exercise Outstanding and Exercisable Warrants Price Per Share Shares Life (Years) $ 1.00 2,000,000 4.74 As of December 31, 2022, 2,000,000 4.74 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.62 0.72 Risk free interest rate From 2.95% 4.00 Volatility From 88.92% 92.87% Dividend Yield 0% Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation. Operating Leases The Company has a lease for an office in Dallas, Texas, classified as an operating lease under ASC 842, Leases. On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “Landlord”) to lease and occupy approximately 2,201 Lease Agreement The Lease Agreement has a term of thirty-eight ( 38 5,778 Base Rent 2.45 Proportionate Rent 16,942 The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 8 The Company has right-of-use assets of $ 133,433 174,241 143,424 185,405 50,826 0 0 SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at September 30, 2023 Amount 2023 $ 17,516 2024 71,716 2025 67,589 - Total lease payments 156,821 Less: Imputed interest (13,397 ) Present value of lease liabilities $ 143,424	NOTE 9 – COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation. Operating Leases The Company has a lease for an office in Dallas, TX classified as operating leases under ASC 842, Leases On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “Landlord”) to lease and occupy approximately 2,201 Lease Agreement The Lease Agreement has a term of thirty-eight ( 38 5,777.63 Base Rent 2.45% Proportionate Rent 16,941.79 The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 8% The Company has right-of-use assets of $ 174,241 185,405 16,942 0 SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at December 31, 2022 Amount 2023 69,515 2024 71,716 2025 67,589 Total lease payments 208,820 Less: Imputed interest (23,415 ) Present value of lease liabilities $ 185,405

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based on the evaluation, the Company identified the following subsequent events: On October 1, 2023, the Company executed a Summary of Terms and Conditions (“Consulting Agreement”) with Gene Johnston (“Johnston”) continuing his appointment as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Consulting Agreement, the Company issued Johnston 50,000 2,000 On October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (“Luca Consulting”), to provide management consulting and business advisory services to the Company during the term of the agreement, which is for three months. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Luca Consulting $ 15,000 200,000 0.60 120,000	NOTE 11 – SUBSEQUENT EVENTS On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“DojoLabs”), to provide various strategic marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay DojoLabs $ 100,000 50,000 0.28 28,000 On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“Bethor”), to provide strategic advisory services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Bethor 250,000 0.28 70,000 On January 6, 2023, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning. In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“Dr. Rudman”) and Mr. Jarrett Boon (“Mr. Boon”), both of whom are independent, non-Board members and non-Company employees, to the Advisory Board. Dr. Rudman will serve as Chairman of the Advisory Board. In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Rudman Consulting Agreement”), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman 25,000 2,000 0.28 7,000 In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Boon Consulting Agreement”), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon 25,000 0.28 7,000 On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. 0.28 98,000

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 8 – GOING CONCERN These financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying financials, the Company had a net loss of $ 1,998,055 2,015,756

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10- INCOME TAXES On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which significantly changed U.S. tax law. The Act lowered the Company’s U.S. statutory federal income tax rate from 35% 21% The Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increases the Company’s deferred tax asset related to the Company’s net operating loss by approximately $ 2,015,756 2,015,756 We record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgement changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2022, and 2021 we have not recorded any uncertain tax positions in our financial statements. The effective US federal income corporate tax rates for 2022 and 2021 are 21% 21% The Company has net operating loss carry forwards of approximately $ 2,015,756 The Company has a deferred tax asset as shown in the following: SCHEDULE OF DEFERRED TAX ASSET Year Ending December 31, 2022 Year Ending December 31, 2021 Deferred Tax Asset 2,015,756 17,701 Valuation Allowance (2,015,756 ) (17,701 ) Net Deferred Tax Asset $ — $ —

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) under the accrual basis of accounting. These financial statements are presented in U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the years ended December 31, 2022 and 2021 included in the Company’s Registration Statement on Form S-1 (Amendment No. 4), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (the “Form S-1”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the Form S-1 have been omitted.	Basis of Presentation Basis of Preparation
Cash Equivalents	Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures a total cash balance of up to $ 250,000 no	Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $ 250,000 no
Income Taxes	Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes	Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”) 740, Income Taxes
Net Loss Per Common Share	Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share 1,400,000 1,250,000 1,063,000 2,000,000	Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earnings per Share 1,250,000 2,000,000
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.	Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ -	Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ -
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5
Concentration and Risks	Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.	Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.
Black Scholes Option Pricing Model	Black Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.	Binomial Calculation Model Black Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)
Related Parties	Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.	Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial statements.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.
Revenue Recognition	Revenue Recognition Our Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.	Revenue Recognition Our Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue is generated by selling directly to consumers through our websites. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.
Inventories	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Marketing and advertising	Marketing and advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations $ 1,633,528 0
Subsequent events	Subsequent events The Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, Subsequent Events	Subsequent events The Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, Subsequent Events

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE	The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ -	The following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021 SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 22,550 $ - $ - Total assets 22,550 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 22,550 $ - $ -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, December 31, Computers $ 5,062 $ 5,062 Equipment 119,819 116,300 Less accumulated depreciation: (22,461 ) (3,863 ) Property and equipment, net $ 102,420 $ 117,499	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2022 December 31, 2021 Computers 5,062 - Equipment 116,300 - Less accumulated depreciation: (3,863 ) - Property and equipment, net 117,499 -

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes common stock options activity: The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised - - Expired - - Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 Outstanding, September 30, 2023 1,250,000 $ 1.10 Granted 150,000 $ 1.10 Exercised - - Expired - - Outstanding, September 30, 2023 1,400,000 $ 1.10 Exercisable, September 30, 2023 454,167 $ 1.10 The weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows: Outstanding Options Exercisable Options Options Exercise Shares Life Weighted Average Shares Weighted Average $ 1.10 1,400,000 4.53 $ 1.10 454,167 $ 1.10	The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised — — Expired — — Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows: Outstanding Options Exercisable Options Options Exercise Price Per Share Shares Life (Years) Weighted Average Exercise Price Shares Weighted Average Exercise Price $ 1.10 1,250,000 4.67 $ 1.10 133,333 $ 1.10
SCHEDULE OF FAIR VALUE ASSUMPTIONS	SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 Risk free interest rate 3.64 3.30 % Volatility 224.70 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term	SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 Risk free interest rate 3.30 % Volatility 92.54 % Dividend Yield 0 % Expected Term 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future. (4) The Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine the overall expected term.
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrant activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised - - Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 Granted 87,500 5.00 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, September 30, 2023 1,063,000 1.30 Exercisable, September 30, 2023 975,500 $ 1.00 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows: Outstanding and Vested Warrants Weighted Average Warrant Exercise Price Per Share Shares Life (Years) $ 1.00 1,063,000 3.83	The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised — — Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows: Warrants Exercise Outstanding and Exercisable Warrants Price Per Share Shares Life (Years) $ 1.00 2,000,000 4.74
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF FAIR VALUE ASSUMPTIONS	SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.37 0.72 Risk-free interest rate From 2.95 4.00 % Volatility From 88.92 92.87 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.	SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.62 0.72 Risk free interest rate From 2.95% 4.00 Volatility From 88.92% 92.87% Dividend Yield 0% Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF MATURITY OF LEASE LIABILITIES	SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at September 30, 2023 Amount 2023 $ 17,516 2024 71,716 2025 67,589 - Total lease payments 156,821 Less: Imputed interest (13,397 ) Present value of lease liabilities $ 143,424	SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at December 31, 2022 Amount 2023 69,515 2024 71,716 2025 67,589 Total lease payments 208,820 Less: Imputed interest (23,415 ) Present value of lease liabilities $ 185,405

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSET	The Company has a deferred tax asset as shown in the following: SCHEDULE OF DEFERRED TAX ASSET Year Ending December 31, 2022 Year Ending December 31, 2021 Deferred Tax Asset 2,015,756 17,701 Valuation Allowance (2,015,756 ) (17,701 ) Net Deferred Tax Asset $ — $ —

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended	5 Months Ended	9 Months Ended		12 Months Ended
	Aug. 08, 2022	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Date of incorporation					Oct. 07, 2021		Oct. 07, 2021
Share issued price per share	$ 1
Net proceeds from issuance of common stock			$ 800		$ 5,000,000	$ 1,500,500	$ 2,000,000
Sale of stock, shares	2,000,000			2,000,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares		1,250,000
Share issued price per share		$ 4
Net proceeds from issuance of common stock		$ 4,350,000
Resale Prospectus [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares		2,000,000
Share issued price per share		$ 1
Sale of stock, shares		4,765,000

SCHEDULEOF FINANCIAL INSTRUMENT

SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash	$ 682,860	$ 22,550
Total assets	682,860	22,550
Total liabilities
Fair value, net asset (liability)	682,860	22,550
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Total assets
Total liabilities
Fair value, net asset (liability)
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Total assets
Total liabilities
Fair value, net asset (liability)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount	$ 250,000		$ 250,000
Cash equivalents	0		$ 0	$ 0
Marketing and advertising expense	$ 1,633,528	$ 0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	5 years		5 years
Options [Member]
Property, Plant and Equipment [Line Items]
Anti-dilutive securities	1,400,000		1,250,000
Warrant [Member]
Property, Plant and Equipment [Line Items]
Anti-dilutive securities	1,063,000		2,000,000

PREPAID EXPENSES AND DEPOSITS (

PREPAID EXPENSES AND DEPOSITS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid expenses related party	$ 11,745	$ 84,382		$ 0
Securtiy deposit			$ 16,942
Master Services Agreement [Member] | Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid the related party expense	$ 15,000

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	$ 21,581

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less accumulated depreciation:	$ (22,461)	$ (3,863)
Property and equipment, net	102,420	117,499
Computers [Member]
Property, Plant and Equipment [Line Items]
Equipment	5,062	5,062
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment	$ 119,819	$ 116,300

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property acquired value		$ 3,519	$ 2,531	$ 43,102
Depreciation expense		18,598		3,863
Property plant and equipment net		$ 102,420		117,499
Property acquired value				$ 121,362

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)						3 Months Ended	9 Months Ended		12 Months Ended
	Aug. 18, 2022	Jun. 29, 2022	Jun. 16, 2022	Mar. 18, 2022	Dec. 10, 2021	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Proceeds from issuance of common stock						$ 800	$ 5,000,000	$ 1,500,500	$ 2,000,000
Repayments of related party debt							89,200	25,070	25,070
Proceeds from related party						$ 39,270		$ 75,000	75,000
Jacob D Cohen [Member]
Related Party Transaction [Line Items]
Repayments of related party debt									248,151
Cohen Enterprises Inc [Member]
Related Party Transaction [Line Items]
Equity ownership interest			80%
Cohen Enterprises Inc [Member]
Related Party Transaction [Line Items]
Related party advances received		$ 25,000
Issuance of shares			8,000,000
Proceeds from issuance of common stock			$ 90,000
Repayments of related party debt	$ 25,000								89,200	$ 39,200
Proceeds from related party							$ 0		$ 89,200
Imputed interest percentage							8%		8%
Related party transaction purchases							$ 8,232		$ 4,674	181
Zip Doctor Inc [Member]
Related Party Transaction [Line Items]
Related party advances received					$ 70
Repayments of related party debt							$ 0		$ 0	70
Imputed interest percentage							8%		8%
Related party transaction purchases									$ 2	$ 0
Stock Purchase Agreement [Member]
Related Party Transaction [Line Items]
Related party advances received				$ 50,000	$ 39,200		$ 89,200
Repayments of related party debt			$ 89,200

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)						9 Months Ended
	Apr. 01, 2023	Mar. 23, 2023	Mar. 01, 2023	Feb. 01, 2023	Jan. 01, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Nov. 18, 2022
Debt Disclosure [Abstract]
Debt instrument face amount									$ 78,260
Debt instrument periodic payment	$ 31,630		$ 5,000	$ 5,000	$ 5,000
Repayments of notes payable		$ 63,260				$ 78,260
Notes payable								$ 78,260

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Options, Outstanding Beginning Balance	1,250,000
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.10
Options, Granted	150,000	1,250,000
Weighted Average Exercise Price, Granted	$ 1.10	$ 1.10
Options, Exercised
Weighted Average Exercise Price, Exercised
Options, Expired
Weighted Average Exercise Price, Expired
Outstanding Ending Balance	1,400,000	1,250,000
Weighted Average Outstanding Price Ending Balance	$ 1.10	$ 1.10
Exercisable Ending Balance	454,167	133,333
Weighted Average Exercisable Price Ending Balance	$ 1.10	$ 1.10
Option Exercise Price Per Share	$ 1.10	$ 1.10
Options Term	4 years 6 months 10 days	4 years 8 months 1 day

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of common stock on measurement date	$ 1	$ 1
Risk-free interest rate		3.30%
Volatility		92.54%
Dividend rate	0%	0%
Expected term		3 years 6 months
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Dividend rate	0%	0%
Expected term	5 years	5 years
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk-free interest rate	3.64%
Volatility	224.70%
Expected term	6 years
Maximum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of common stock on measurement date	$ 0.72	$ 0.72
Risk-free interest rate	4%	4%
Volatility	92.87%	92.87%
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk-free interest rate	3.30%
Volatility	92.54%
Expected term	3 years 6 months
Minimum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of common stock on measurement date	$ 0.37	$ 0.62
Risk-free interest rate	2.95%	2.95%
Volatility	88.92%	88.92%

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Beginning Balance	2,000,000
Weighted Average Exercise Price Beginning Balance	$ 1
Warrants Granted	87,500	2,210,070
Weighted Average Exercise Price Granted	$ 5	$ 1
Warrants Exercised	(1,024,500)
Weighted Average Exercise Price Exercised	$ 1
Warrants Expired
Weighted Average Exercise Price Expired
Warrants Cancelled		(210,070)
Weighted Average Exercise Price Cancelled		$ 1
Warrants Outstanding, Ending balance	1,063,000	2,000,000
Weighted Average Exercise Price Ending Balance	$ 1.30	$ 1
Warrants Exercisable Ending balance	975,500	2,000,000
Weighted Average Exercise Price Exercisable price	$ 1	$ 1
Outstanding and Vested Warrants Ending balance	1,063,000	2,000,000
Outstanding and Vested Warrants Expected Term	3 years 9 months 29 days	4 years 8 months 26 days
Warrants Exercise Price Per Share		$ 1

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)																																	1 Months Ended	3 Months Ended						5 Months Ended	9 Months Ended	12 Months Ended
	Jun. 27, 2023	Jun. 22, 2023	Jun. 21, 2023	Jun. 08, 2023	Jun. 07, 2023	Jun. 06, 2023	Jun. 01, 2023	May 25, 2023	May 01, 2023	Apr. 26, 2023	Apr. 25, 2023	Apr. 24, 2023	Apr. 01, 2023	Mar. 22, 2023	Mar. 20, 2023	Mar. 01, 2023	Feb. 01, 2023	Jan. 24, 2023	Jan. 06, 2023	Jan. 03, 2023	Jan. 01, 2023	Dec. 21, 2022	Dec. 09, 2022	Nov. 01, 2022	Oct. 14, 2022	Oct. 13, 2022	Oct. 01, 2022	Sep. 15, 2022	Sep. 06, 2022	Aug. 08, 2022	Jun. 23, 2022	Apr. 06, 2022	Mar. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 30, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized																																		10,000,000					10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock par value																																		$ 0.0001					$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized																																		200,000,000					200,000,000	200,000,000	200,000,000	200,000,000
Common stock par value																																		$ 0.0001					$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock shares issued																																		16,789,500					8,000,000	13,365,000	16,789,500	13,365,000
Common stock shares outstanding																																		16,789,500					8,000,000	13,365,000	16,789,500	13,365,000
Shares issued value																																				$ 5,000,000	$ 1,500,500					$ 2,000,000
Share price																														$ 1
Warrants term																														5 years
Exercise price																														$ 1
Sale of stock, shares																														2,000,000										2,000,000
Warrants issued																																								2,000,000		2,000,000
Fair value of warrants															$ 31,995																											$ 1,438,299
Paid in cash																																		$ 84,750	$ 387,000	700,000	265,000	$ 225,000	$ 800			$ 540,065
Debt instrument periodic payment													$ 31,630			$ 5,000	$ 5,000				$ 5,000
Number of options																																		1,400,000						1,250,000	1,400,000	1,250,000
Number of options granted																																									150,000	1,250,000
Exercise price																																		$ 1.10						$ 1.10	$ 1.10	$ 1.10
Share based compensation																																									$ 197,954	$ 82,267
Fair value of options outstanding																																		$ 640,194						$ 688,984	640,194	$ 688,984
Warrants issued for services																																								210,070		210,070
Fair value of warrant																																										$ 151,821
Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value of warrants outstanding																																		$ 581,264						$ 1,438,299	581,264	1,438,299
Service Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																																									$ 27,842	$ 27,842
Share price																																		$ 0.28						$ 0.28	$ 0.28	$ 0.28
Consulting Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																		$ 350,000
Share price																		$ 1
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																																				$ 125	$ 150					$ 200
Sale of stock, shares														1,250,000
Shares issued																																				1,250,000	1,500,500					2,000,000
Shares issued in consideration																																		75,000	375,000	700,000	265,000	2,250,000	8,000,000			3,365,000
Paid in cash																																		$ 8	$ 37	$ 70	$ 27	$ 225	$ 800			$ 337
Share price														$ 4
Gross proceeds														$ 5,000,000
Exercise price									$ 1.10
Vesting term									3 years																																	3 years
Common Stock [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options									150,000																															1,250,000		1,250,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding																																		1,063,000						2,000,000	1,063,000	2,000,000
Outstanding and vested warrants expected term																																									3 years 9 months 29 days	4 years 8 months 26 days
Mrs.Hammer [Member]
Subsidiary, Sale of Stock [Line Items]
Shares vested									50,000
Annual salary									$ 150,000
Share based compensation arrangement by share-based payment award, description									The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $1.00 per share, with options to purchase 50,000 shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and Mrs. Hammer.
Exercise price									$ 1
Chief Executive Officer [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price																																								$ 1.10		$ 1.10
Chief Executive Officer [Member] | Common Stock [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options granted																																										750,000
Chief Operating Officer [Member] | Common Stock [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options granted																																										500,000
Greentree Financial Group [Member] | Service Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																																									$ 84,750
Share price																																		$ 1.13							$ 1.13
Chartered Services LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Paid in cash																						$ 150,000
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from investors																														$ 2,000,000
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																																$ 0.10
Shares issued in consideration																																1,000,000
Paid in cash																																$ 100,000
Restricted Stock Units (RSUs) [Member] | Chief Operating Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																																$ 0.10
Shares issued in consideration																																1,000,000
Paid in cash																																$ 100,000
Restricted Stock Units (RSUs) [Member] | Leov Law Firm [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																															$ 0.10
Shares issued in consideration																															250,000
Paid in cash																															$ 25,000
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Settlement description																		the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.
Restricted Stock [Member] | Consulting Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																		$ 98,000
Share price																		$ 0.28
Settlement description																		the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.
Restricted Stock [Member] | David Sandler [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																												$ 2,784
Share price																												$ 0.28
Shares issued																												10,000
Restricted Stock [Member] | Hsiaoching Chou [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																												$ 1,392
Share price																												$ 0.28
Shares issued																												5,000
Restricted Stock [Member] | Chief Financial Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																											$ 41,763
Share price																											$ 0.28
Restricted common stock issued																											150,000
Shares vested																								25,000			25,000
Restricted Stock [Member] | Director [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted common stock issued																										75,000
Restricted stock issued net																										225,000
Restricted Stock [Member] | Director [Member] | 2022 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																									$ 20,881
Share price																									$ 0.28
Restricted Stock [Member] | Joan Arango [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																									$ 7,204
Share price																									$ 0.28
Restricted Stock [Member] | Joan Arango [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted common stock issued																									25,000
Restricted Stock [Member] | Dr.Rudman [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 7,000
Share price																			$ 0.28
Shares issued																			25,000
Compensation expense																			$ 2,000
Restricted Stock [Member] | Dr.Rudman [Member] | Advisor Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 25,000
Share price																			$ 1
Shares issued																			25,000
Compensation expense																			$ 2,000
Restricted Stock [Member] | Mr.Boon [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 7,000
Share price																			$ 0.28
Shares issued																			25,000
Restricted Stock [Member] | Mr.Boon [Member] | Advisor Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 25,000
Share price																			$ 1
Shares issued																			25,000
Restricted Stock [Member] | Mr Andrew [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value								$ 55,000
Share price								$ 1.10
Restricted Stock [Member] | Mr Andrew [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued								50,000
Restricted Stock [Member] | Major Dodge [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value							$ 22,000
Share price							$ 1.10
Restricted Stock [Member] | Major Dodge [Member] | 2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued							20,000
Restricted Stock [Member] | PHX Global LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																													$ 13,921
Share price																													$ 0.28
Shares issued																													50,000
Restricted Stock [Member] | Ezekiel Elliott [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																													$ 27,842
Share price																													$ 0.28
Shares issued																													100,000
Restricted Stock [Member] | Greentree Financial Group [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued in consideration																																									100,000	100,000
Paid in cash																																									$ 50,000	$ 50,000
Settlement description																																									(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023	(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023
Restricted Stock [Member] | Greentree Financial Group [Member] | Service Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued in consideration																																									75,000
Paid in cash																																									$ 40,000
Settlement description																																									(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024.
Restricted Stock [Member] | Greentree Financial Group [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued																																									100,000	100,000
Restricted Stock [Member] | White Unicorn LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																								$ 28,816
Share price																								$ 0.28
Shares issued																								100,000
Restricted Stock [Member] | Global Career Networks Inc [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																							$ 28,816
Share price																							$ 0.28
Shares issued																							100,000
Restricted Stock [Member] | Chartered Services LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																						$ 72,039
Share price																						$ 0.28
Settlement description																						with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000
Restricted Stock [Member] | Dojo Labs [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																				$ 28,000
Share price																				$ 0.28
Shares issued																				50,000
Cash																				$ 100,000
Restricted Stock [Member] | Dojo Labs [Member] | Consulting Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																				$ 100,000
Share price																				$ 1
Restricted Stock [Member] | Bethor Ltd [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 70,000
Share price																			$ 0.28
Shares issued																			250,000
Restricted Stock [Member] | Bethor Ltd [Member] | Consulting Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																			$ 250,000
Share price																			$ 1
Shares issued																			250,000
Restricted Stock [Member] | Street Group LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value							$ 55,000
Share price							$ 1.10
Shares issued							50,000
Debt instrument periodic payment							$ 5,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value																														$ 2,000,000
Private Placement Warrant One [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued						150,000						100,000
Sale of stock price						$ 1						$ 1
Consideration paid						$ 150,000					$ 100,000	$ 100,000
Private Placement Warrant Two [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued					75,000						100,000
Sale of stock price					$ 1						$ 1
Consideration paid					$ 75,000
Private Placement Warrant Three [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued				24,500							25,000
Sale of stock price				$ 1							$ 1
Consideration paid				$ 24,500							$ 25,000
Private Placement Warrant Four [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued			100,000								25,000
Sale of stock price			$ 1								$ 1
Consideration paid			$ 100,000								$ 25,000
Private Placement Warrant Five [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued		100,000									75,000
Sale of stock price		$ 1									$ 1
Consideration paid		$ 100,000									$ 75,000
Private Placement Warrant Six [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued		25,000								100,000
Sale of stock price		$ 1								$ 1
Consideration paid		$ 25,000								$ 100,000
Private Placement Warrant Seven [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants issued	100,000								25,000
Sale of stock price	$ 1								$ 1
Consideration paid	$ 100,000								$ 25,000
Private Placement Warrant [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued value									$ 180,000
Shares issued									180,000
Share price									$ 1
Consideration paid									$ 300,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																																	$ 4			$ 4
Shares issued																																	1,250,000
IPO [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price															$ 5
Warrants issued															87,500

SCHEDULE OF MATURITY OF LEASE L

SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Remainder of Fiscal Year	$ 17,516
Year One	71,716	$ 69,515
Year Two	67,589	71,716
Year Three		67,589
Total lease payments	156,821	208,820
Less: Imputed interest	(13,397)	(23,415)
Present value of lease liabilities	$ 143,424	$ 185,405

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)		9 Months Ended		12 Months Ended
	Sep. 28, 2022 USD ($) ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	2,201
Operating lease, description	The Lease Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, from months 3-18, which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term
Lease term	38 months
Base rent	$ 5,777.63
Percentage of proportionate rent	2.45%
Percentage of incremental borrowing rate	8%
Right of use of asset		$ 133,433		$ 174,241
Operating lease liability		143,424		185,405
Operating lease expense		50,826	$ 0	16,942
Asset impairment charges		$ 0	$ 0	$ 0
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, description	The Lease Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,778, or $31.50 per square foot, for the from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term
Base rent	$ 16,941.79

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)						3 Months Ended		12 Months Ended
	Oct. 10, 2023	Oct. 01, 2023	Jan. 24, 2023	Jan. 06, 2023	Jan. 03, 2023	Mar. 31, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 08, 2022
Subsequent Event [Line Items]
Shares issued value						$ 5,000,000	$ 1,500,500	$ 2,000,000
Share price									$ 1
Restricted Stock [Member]
Subsequent Event [Line Items]
Settlement description			the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.
Restricted Stock [Member] | Dr.Rudman [Member]
Subsequent Event [Line Items]
Shares issued				25,000
Shares issued value				$ 7,000
Share price				$ 0.28
Compensation expense				$ 2,000
Restricted Stock [Member] | Mr.Boon [Member]
Subsequent Event [Line Items]
Shares issued				25,000
Shares issued value				$ 7,000
Share price				$ 0.28
Dojo Labs [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares issued					50,000
Shares issued value					$ 28,000
Share price					$ 0.28
Cash					$ 100,000
Bethor Ltd [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares issued				250,000
Shares issued value				$ 70,000
Share price				$ 0.28
Consulting Agreement [Member] | Dojo Labs [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares issued value					$ 100,000
Share price					$ 1
Consulting Agreement [Member] | Bethor Ltd [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares issued				250,000
Shares issued value				$ 250,000
Share price				$ 1
Consulting Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued		50,000
Shares issued value		$ 2,000
Consulting Agreement [Member] | Subsequent Event [Member] | Luca Consulting, LLC [Member]
Subsequent Event [Line Items]
Shares issued	200,000
Shares issued value	$ 120,000
Stock value paid in cash	$ 15,000
Share price	$ 0.60
Consulting Agreements [Member]
Subsequent Event [Line Items]
Shares issued value			$ 350,000
Share price			$ 1
Consulting Agreements [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares issued value			$ 98,000
Share price			$ 0.28
Settlement description			the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended							9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,799,460	$ 2,284,025	$ 2,560,885	$ 994,915	$ 310,185	$ 19,599	$ 17,701	$ 6,644,370	$ 1,324,400	$ 1,998,055
Accumulated deficit	$ 8,660,126						$ 17,701	$ 8,660,126		$ 2,015,756

SCHEDULE OF DEFERRED TAX ASSET

SCHEDULE OF DEFERRED TAX ASSET (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 2,015,756	$ 17,701
Valuation Allowance	(2,015,756)	(17,701)
Net Deferred Tax Asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Dec. 22, 2017	Dec. 31, 2022	Dec. 31, 2021
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Deferred tax asset		$ 2,015,756	$ 17,701
Deferred tax assets, valuation allowance		$ 2,015,756	$ 17,701
US federal income corporate tax rates, percentage		21%	21%
Net operating loss carry forwards		$ 2,015,756
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory federal income tax rate, percentage	35%
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory federal income tax rate, percentage	21%